Open AccessGuillain-Barré Syndrome due to Covid-19: A Review
Author(s) -
Julia Carvalho Folly,
Lara Emanuelle Silva Reis,
Stella Maris Lins Terrena
Publication year - 2021
Language(s) - English
Resource type - Conference proceedings
DOI - 10.5327/1516-3180.553
Subject(s) - guillain barre syndrome , medicine , pandemic , covid-19 , virus , immune system , medline , immunology , pediatrics , disease , biology , biochemistry , infectious disease (medical specialty)
Background: With the pandemic of SARS-CoV-2 virus spreading, there has been an increase in the dissemination of information relating the infection to neuromuscular involvement. Articles indicate an increase in cases of GuillainBarré Syndrome immediately or a few weeks after infection by the virus. Objectives: The present study aimed to gather the current knowledge disclosed in the literature about the onset of Guillain-Barré Syndrome (GBS) related to SARS-CoV-2 infection. Methods: The study design was based on PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses), using the Pubmed database, including articles in Portuguese and English language. Results: Articles that indicated an increase in cases of Guillain-Barré Syndrome dated to publications in April 2020 of cases analyzed since February of the same year. Histopathological analyses that identified the virus in the central nervous system of patients, associated with the detection of anti-anglioside antibodies of the anti-GM1, anti-GD1a and anti-GD1b types in the patients analyzed, represent important findings about GBS associated with Covid-19. Pro-inflammatory cytokines present in the immune response as a result of SARS-COV-2 have been associated with the triggering of neuronal injury. In patients analyzed we observed the manifestation of symptoms between 5 and 21 days after Covid-19 infection, similar to the reported GBS interval after other viral infections. Conclusion: The clinical pictures of patients affected by Covid-19 suggest an intense possible relating between infection by the new coronavirus and autoimmune neuromuscular conditions. Further studies are needed on this association, which has not yet been clarified.